8,0000 zł
0,00% 0,0000 zł
SOPHARMA AD (SPH)

Q2 2019 Individual financial report of Sopharma AD

Spis treści:

1. REPORT

2. INFORMATION ABOUT THE ENTITY

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY


Spis załączników:
3JR_Financial_statements_Q2_2019_EN.rar  (REPORT)

POLISH FINANCIAL SUPERVISION AUTHORITY
UNI - EN REPORT No 33 / 2019
Date of issue: 2019-07-30
Short name of the issuer
SOPHARMA AD
Subject
Q2 2019 Individual financial report of Sopharma AD
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
Financial report according to IFRS as at 30 June 2019
Notes to the financial report as at 30 June 2019
Management report as at 30 June 2019
Insider information as at 30 June 2019
Additional information as at 30 June 2019
Financial report according to BFSC standards as at 30 June 2019
Annex 9 as at 30 June 2019
Declaration as at 30 June 2019
Notification - Main export markets gain speed in H1 2019
Annexes
File Description
3JR_Financial_statements_Q2_2019_EN.rar3JR_Financial_statements_Q2_2019_EN.rar Q2 2019 Individual financial report of Sopharma AD

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2019-07-30 Ognian Donev Executive director
Źródło: GPW - komunikaty spółek (ESPI)
Dodałeś komentarz Twój komentarz został zapisany i pojawi się na stronie za kilka minut.

Jeszcze nikt nie skomentował tego artykułu - Twój komentarz może być pierwszy.

Nowy komentarz

Anuluj
Polecane
Najnowsze
Popularne
Przejdź do strony za 5 Przejdź do strony »

Czy wiesz, że korzystasz z adblocka?
Reklamy nie są takie złe

To dzięki nim możemy udostępniać
Ci nasze treści.